Cargando...
Omacetaxine mepesuccinate in the treatment of intractable chronic myeloid leukemia
In a significant proportion of patients with chronic myeloid leukemia, resistance to BCR-ABL tyrosine kinase inhibitors develops due to acquisition of BCR-ABL kinase domain mutations and insensitivity of leukemia stem cells to tyrosine kinase inhibitors. Omacetaxine mepesuccinate (formerly called ho...
Gardado en:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
Dove Medical Press
2014
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3916637/ https://ncbi.nlm.nih.gov/pubmed/24516334 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OTT.S41786 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|